Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHypera SA

Hypera SA

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
4.0 USD -0.02 ( 0.50%)
Last update at 2026-11-09T15:15:00Z
VOLUME
5000
Market Cap
3203.18M
P/E
8.75

Momentum Score

…

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.00
Low
4.00
High
52 Week Price Range
3.67
Low
4.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Hypera S.A. is a Brazil-based pharmaceutical and consumer health company that develops, manufactures and markets prescription drugs, over-the-counter products and consumer brands domestically and in selected international markets. Long-term growth may be supported by Brazil's large healthcare market, portfolio diversification, scale in manufacturing and distribution, and expansion of branded generics and OTC channels.
Major risks include Brazilian macro and currency volatility, government pricing and regulatory actions, competitive pressure from generics and multinationals, and execution risks around new launches and acquisitions.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.02
Dividend Yield
4.61%
Revenue TTM
8818.79M
Revenue Per Share
13.49
Gross Profit TTM
5394.43M
Debt / Equity
0.75
ROE
13.16%
Net Debt
7691.91M
ROCE
9.24%
Diluted EPS TTM
0.52

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 900.07M 979.24M 1509.47M 1611.10M 1644.33M
Minority interest 5.24M 10.12M -3.20M -1.70M -0.10M
Net income 1195.37M 1340.99M 1647.96M 1696.70M 1330.21M
Selling general administrative 73.22M 89.28M 348.12M 92.81M 67.42M
Selling and marketing expenses 2198.87M 2036.55M 2172.41M 1760.19M 1481.05M
Gross profit 4545.51M 4381.00M 4995.54M 4761.52M 3802.89M
Reconciled depreciation 317.22M 281.06M 218.66M 169.10M 133.69M
Ebit 1943.74M 1950.29M 2638.62M 2642.63M 2036.29M
Ebitda 2260.97M 2231.34M 2876.94M 2811.74M 2169.98M
Depreciation and amortization 317.22M 281.06M 238.31M 169.10M 133.69M
Operating income 1738.05M 1795.77M 2285.25M 2642.63M 2036.29M
Other operating expenses 5961.11M 5646.70M 5629.41M 5087.13M 3985.21M
Interest expense 1043.67M 971.05M 1349.52M 986.08M 383.22M
Tax provision -290.75M -353.76M -117.97M -95.35M 26.58M
Interest income 47.59M 35.15M 64.21M 70.85M 35.93M
Net interest income -1082.12M -1043.62M -1193.61M -1006.37M -400.43M
Income tax expense -290.75M -353.76M -141.64M -95.35M 26.58M
Total revenue 7699.16M 7442.47M 7914.66M 7546.35M 5937.37M
Total operating expenses 2807.46M 2585.23M 2710.30M 2302.30M 1850.72M
Cost of revenue 3153.65M 3061.47M 2919.11M 2784.83M 2134.49M
Total other income expense net -837.98M -816.53M -775.77M -1031.53M -391.96M
Discontinued operations - - - -8.05M -287.44M
Net income from continuing ops 1190.83M 1333.00M 1775.01M 1706.45M 1617.75M
Net income applicable to common shares - - - 1696.70M 1330.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 25158.00M 24559.08M 24508.75M 23755.63M 19817.96M
Intangible assets 4716.64M 4450.52M 4092.74M 3729.66M 2630.37M
Other current assets 629.05M 749.28M 663.00M 391.06M 232.35M
Total liab 12633.63M 12457.26M 12990.88M 13100.19M 9984.49M
Total stockholder equity 12522.03M 12096.28M 11504.12M 10645.76M 9826.59M
Deferred long term liab - - - 858.61M 568.87M
Other current liab 2038.68M 1477.58M 1409.09M 1616.79M 1383.28M
Common stock 9705.89M 9705.89M 4478.13M 4478.13M 4478.13M
Capital stock 9705.89M 9705.89M 4478.13M 4478.13M 4478.13M
Retained earnings 1065.34M 1509.48M 6135.13M 5266.25M 4360.24M
Other liab - - - 405.28M 345.39M
Good will 7340.33M 7340.33M 7339.10M 7365.81M 7366.79M
Other assets - - -2817.25M 30.66M 1691.90M
Cash 1645.54M 1739.33M 2580.89M 2862.47M 2287.06M
Total current liabilities 4110.97M 3940.09M 4644.24M 5225.19M 2776.53M
Current deferred revenue - - 700.73M - -
Net debt 7691.91M 7658.04M 7380.94M 6818.50M 5119.31M
Short term debt 1329.91M 1409.00M 2141.00M 2298.76M 602.49M
Short long term debt 1329.91M 1409.00M 2141.00M 2298.76M 565.65M
Short long term debt total 9337.45M 9397.37M 9961.84M 9680.97M 7406.37M
Other stockholder equity -12.39M -22.83M -20.28M 6167.63M 5348.47M
Property plant equipment - - - 2814.54M 2095.14M
Total current assets 6048.36M 6681.88M 8077.77M 8530.12M 6491.63M
Net tangible assets - - - 408.89M 398.30M
Short term investments - - 161.43M - -518.29M
Net receivables 1694.59M 2254.67M 2642.15M 3080.61M 2668.74M
Long term debt 8007.54M 7988.36M 7820.84M 7382.21M 6795.34M
Inventory 2079.18M 1938.60M 2191.73M 2195.98M 1303.48M
Accounts payable 575.41M 984.14M 389.67M 1309.65M 790.76M
Accumulated other comprehensive income 1761.77M 903.74M 911.14M - -
Non currrent assets other 204.01M 366.45M 1317.88M 712.33M 249.62M
Non current assets total 19109.64M 17877.21M 16430.99M 15225.51M 13326.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -592.44M -847.86M -1742.34M -4412.43M
Change to liabilities - - - 91.67M 28.88M
Total cashflows from investing activities -689.50M -592.44M -791.19M -1742.34M -4412.43M
Net borrowings -240.19M -757.48M 296.71M 2010.27M 1701.50M
Total cash from financing activities -1978.71M -2788.73M -1886.38M 278.95M 557.06M
Change to operating activities - - - 464.39M 275.04M
Net income 899.18M 975.51M 1506.99M 1597.82M 1209.33M
Change in cash -93.79M -841.57M -281.58M 575.41M -2456.24M
Begin period cash flow 1739.33M 2580.89M 2862.47M 2287.06M 4743.30M
End period cash flow 1645.54M 1739.33M 2580.89M 2862.47M 2287.06M
Total cash from operating activities 2574.43M 2539.60M 2395.99M 2038.79M 1399.13M
Issuance of capital stock 10.55M 13.25M 81.59M 84.31M 18.69M
Depreciation 317.22M 281.06M 230.28M 169.10M 133.69M
Other cashflows from investing activities -137.32M -150.16M -202.94M -5.80M 168.57M
Dividends paid 627.78M 787.29M 759.88M -806.21M -745.94M
Change to inventory -312.34M 80.12M -90.97M -961.65M -405.54M
Change to account receivables 555.19M 536.13M 243.00M -471.37M -511.81M
Sale purchase of stock -23.09M -55.81M -88.45M -87.00M -128.67M
Other cashflows from financing activities -1098.20M -1201.40M -1374.24M 1552.58M 1932.65M
Change to netincome - - - 854.25M 684.09M
Capital expenditures 799.36M 772.27M 812.71M 1509.46M 838.88M
Change in working capital 378.41M 696.24M -467.66M -726.52M -743.88M
Stock based compensation 22.98M 33.20M 46.20M 24.88M 24.95M
Other non cash items 956.63M 553.59M 1080.19M 973.52M 314.93M
Free cash flow 1775.07M 1767.33M 1583.28M 529.34M 560.25M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HYPMY
Hypera SA		 -0.02
0.50%		 4.00 8.75 7.26 0.36 1.14 2.54 7.38
MKKGY
Merck KGaA ADR		 0.49
1.48%		 33.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.05
0.24%		 20.97 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

Hypera SA

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Av. Magalhães de Castro, 4800, São Paulo, SP, Brazil, 05676-120

55 11 3627 4206

https://www.hypera.com.br

10564

Name Title Year Born
Mr. Breno Toledo Pires de Oliveira CEO & Director NA
Mr. Adalmario Ghovatto Satheler do Couto Investor Relations Officer & CFO NA
Mr. Carlos Roberto Scorsi Chief Operating officer 1962
Juliana Aguinaga Damião Salem Sr. Legal Officer NA
Joao Felipe Khamis Aguilar Risks & Compliance Officer NA
Mr. Luiz Eduardo Sales Clavis VP of Sales & Marketing NA
Mauricio Christovam Sr. HR Officer NA
Mr. Nelson José de Mello Chief Corp. Relations Officer 1959
Mr. Hélio Segouras Head of Consumer Health NA
Mr. Martim Prado Mattos Sec. 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…